retatrutide type 2 diabetes phase 2 weight loss trial 2024 Retatrutide, an experimental weight-loss drug Retatrutide is coming! , There

To confirm availability in your area, complete the quiz on fh.co and check with a licensed provider during your consultation

7 As the first approved dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, tirzepatide demonstrated weight loss exceeding 20% in its pivotal trials, establishing a new therapeutic ceiling

But it also means that simply taking oral GLP-1 would be ineffective, as it would be degraded before reaching systemic circulation

They have added benefits for heart health, including helping to lower blood pressure and improve cholesterol levels

Supporting Data: Studies show that protein-rich meals can increase GLP-1 secretion by 25-40%, depending on the protein type

It effectively helps to reduce fat in targeted areas, especially if previous diets have not achieved the desired weight loss